Filter

51 - 60 of 466 Results

  • Prescription Drug Coverage for the Medicare Population

    Report

    Diane Rowland, executive director of the Commission, testified to the Subcommittee on Health of the U.S. House Committee on Energy and Commerce about providing prescription drugs to seniors. Her testimony includes discussion of Medicaid's role in providing outpatient drug coverage. Testimony Chart Pack

  • National Survey of Physicians 2006: Full Topline Results

    Poll Finding

    National Survey of Physicians 2006: Full Topline Results These toplines provide additional findings from a 2006 national survey of physicians on their views and experiences on a wide range of health care issues. Toplines (.pdf)

  • Views of the New Medicare Drug Law – Toplines

    Poll Finding

    This document includes the toplines from a comprehensive survey of people on Medicare and their attitudes toward the new Medicare drug law. The survey provides detailed insight in their perceptions and opinions about the law, the Medicare-approved drug-discount card program and the new Medicare drug benefit set to begin in January 2006. It also assesses views on the law’s implications for the 2004 elections. Survey Toplines (.pdf)

  • March/April 2005 Kaiser Health Poll Report – Toplines

    Poll Finding

    Health News Index March/April, 2005 The March/April Kaiser Health Poll Report featured topic explores the public's views on the Medicare prescription drug benefit. This featured topic covers the historical perspective from before the law was passed as well as current views and understanding of the benefit, including how seniors are getting information about this plan, whether they think they have enough information and whether or not they plan to enroll. Additionally, the featured topic explores…

  • Kaiser Family Foundation/Harvard School of Public Health National Survey of the Public’s Views on Medicare

    Poll Finding

    Kaiser Family Foundation/Harvard School of Public Health National Survey of the Public's Views on Medicare A new national survey by the Kaiser Family Foundation and the Harvard School of Public Health examines the public's attitudes and opinions on issues related to the Medicare reform and prescription drug debate. The survey also takes a separate look at the differing views of younger and older Americans on this topic. Toplines/Survey (.pdf)

  • Key Facts About Medicare Drug Price Negotiation

    Issue Brief

    Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

  • NPR/Kaiser Family Foundation/Harvard Kennedy School of Government Survey on Health Care – Chart Pack

    Poll Finding

    New NPR/Kaiser Family Foundation/Harvard Kennedy School of Government Survey on Health Care A new survey by NPR, the Kaiser Family Foundation, and Harvard s Kennedy School of Government finds that many Americans have real problems when it comes to accessing and paying for health care, and even if they haven't yet faced a problem, many worry about getting and paying for care in the future. The survey also shows that, while people think helping seniors…

  • Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending

    News Release

    Twenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis. The 20 drugs include 18 drugs available to beneficiaries covered under Medicare Part D (typically drugs purchased at the pharmacy) and two drugs covered under Medicare Part B (physician-administered drugs). The list includes drugs…

  • What Could New Anti-Obesity Drugs Mean for Medicare?

    Policy Watch

    In this piece, we discuss Medicare coverage of obesity treatments, the potential cost implications if Medicare covers anti-obesity drugs, and how the Inflation Reduction Act could potentially address these cost concerns.